BOSTON, MA - PAREXEL International Corporation, a leading global biopharmaceutical services organization, today announced the launch of its Active Tracking service. The service follows Good Distribution Practice (GDP) requirements by providing biopharmaceutical companies with near real-time temperature and location monitoring of investigational medicinal products (IMPs) from central distribution centers to clinical trial sites. An increasing number of medicinal products require a temperature-controlled supply chain to maintain product integrity during transport, including approximately 75 percent of biological drugs, 10 to 15 percent of small molecule therapies, 100 percent of vaccines, and a large percent of biologic samples and diagnostic tools. Temperature deviations and shipment delays can impact patient safety, create patient retention issues, and cause additional manufacturing and shipment costs. Supported by PAREXEL’s Clinical Trial Supply & Logistics global depot and service network, PAREXEL’s Active Tracking service utilizes supply chain monitoring technology to detect incidents, such as shipment delays, shipment diversions, and temperature deviations. When combined with PAREXEL ClinPhone RTSM interactive response technology (IRT), temperature and location data is automatically sent in near real-time to clinical trial sites for assessment. This integration enables greater automated preventive or remedial actions, such as release, quarantine, and automatic re-order of temperature-controlled products, simplifying temperature management for sites and sponsors. “In the past, an investigational site had to wait until it received a shipment and downloaded the data from the temperature logger to find out if a drug’s temperature had been compromised,” said Sanjay Vyas, Corporate Vice President, Clinical Trial Supplies & Logistics, PAREXEL. “With PAREXEL’s Active Tracking service, we can monitor IMPs from packaging at our depots through transit to clinical trial sites, in near real-time. This innovation in clinical supply chain management allows us to quickly respond to any temperature complications, which can reduce safety risks for patients as well as manufacturing and shipment costs for clients.” About PAREXEL International PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 84 locations in 51 countries around the world, and had approximately 18,600 employees in the fourth quarter. For more information about PAREXEL International visit www.PAREXEL.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.